Zhejiang Medicine Co Ltd Asset Resilience Ratio
Zhejiang Medicine Co Ltd asset resilience ratio. Zhejiang Medicine Co Ltd (600216) has an Asset Resilience Ratio of 1.85% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zhejiang Medicine Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zhejiang Medicine Co Ltd (2001–2025)
Asset resilience ratio of Zhejiang Medicine Co Ltd from 2001 to 2025. This chart shows how Zhejiang Medicine Co Ltd's Asset Resilience Ratio has changed over time. Read Zhejiang Medicine Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 600216 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥262.29 Million | 1.85% |
| Total Liquid Assets | CN¥262.29 Million | 1.85% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Medicine Co Ltd maintains only 1.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Medicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Medicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Porton Fine Chemicals Ltd
SHE:300363 |
Drug Manufacturers - Specialty & Generic | 6.85% |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA |
Drug Manufacturers - Specialty & Generic | 1.26% |
Zhejiang Medicine Co Ltd Asset Resilience Ratio by Year (2001–2025)
Zhejiang Medicine Co Ltd asset resilience ratio by year from 2001 to 2025. The table below shows the annual Asset Resilience Ratio data for Zhejiang Medicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.78% | CN¥250.32 Million ≈ $36.63 Million |
CN¥14.09 Billion ≈ $2.06 Billion |
-0.36pp |
| 2024-12-31 | 2.14% | CN¥294.91 Million ≈ $43.15 Million |
CN¥13.80 Billion ≈ $2.02 Billion |
-0.43pp |
| 2023-12-31 | 2.57% | CN¥328.31 Million ≈ $48.04 Million |
CN¥12.78 Billion ≈ $1.87 Billion |
-1.03pp |
| 2022-12-31 | 3.60% | CN¥447.29 Million ≈ $65.45 Million |
CN¥12.43 Billion ≈ $1.82 Billion |
-0.03pp |
| 2021-12-31 | 3.63% | CN¥454.40 Million ≈ $66.49 Million |
CN¥12.53 Billion ≈ $1.83 Billion |
+1.05pp |
| 2020-12-31 | 2.58% | CN¥270.73 Million ≈ $39.62 Million |
CN¥10.50 Billion ≈ $1.54 Billion |
-0.59pp |
| 2019-12-31 | 3.17% | CN¥328.63 Million ≈ $48.09 Million |
CN¥10.36 Billion ≈ $1.52 Billion |
+3.08pp |
| 2018-12-31 | 0.09% | CN¥8.68 Million ≈ $1.27 Million |
CN¥10.05 Billion ≈ $1.47 Billion |
+0.08pp |
| 2017-12-31 | 0.01% | CN¥778.05K ≈ $113.85K |
CN¥9.79 Billion ≈ $1.43 Billion |
0.00pp |
| 2013-12-31 | 0.01% | CN¥670.65K ≈ $98.14K |
CN¥7.56 Billion ≈ $1.11 Billion |
0.00pp |
| 2012-12-31 | 0.01% | CN¥891.75K ≈ $130.49K |
CN¥7.06 Billion ≈ $1.03 Billion |
+0.00pp |
| 2010-12-31 | 0.01% | CN¥570.00K ≈ $83.41K |
CN¥4.64 Billion ≈ $678.56 Million |
-0.08pp |
| 2006-12-31 | 0.09% | CN¥2.25 Million ≈ $329.25K |
CN¥2.53 Billion ≈ $369.98 Million |
+0.05pp |
| 2005-12-31 | 0.04% | CN¥898.23K ≈ $131.44K |
CN¥2.21 Billion ≈ $323.07 Million |
-0.02pp |
| 2004-12-31 | 0.06% | CN¥1.17 Million ≈ $171.50K |
CN¥1.84 Billion ≈ $269.09 Million |
-0.12pp |
| 2002-12-31 | 0.19% | CN¥3.06 Million ≈ $447.34K |
CN¥1.64 Billion ≈ $239.50 Million |
+0.06pp |
| 2001-12-31 | 0.13% | CN¥2.00 Million ≈ $292.66K |
CN¥1.57 Billion ≈ $229.03 Million |
-- |
About Zhejiang Medicine Co Ltd
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin. It also provides fat-soluble vitamins, quinolone antibiotics, anti-drug-resistant antibiotics, and other products, as well… Read more